Loading
The first drug aimed specifically at KRAS G12D, the single most common mutation in pancreatic cancer. Early combination data in 2026 showed half of previously treated patients responding.
Revolution Medicines' covalent tri-complex inhibitor of KRAS G12D(ON). Breakthrough Therapy designation in G12D NSCLC (2025). At ESMO GI 2026, zoldonrasib plus daraxonrasib in previously treated RAS G12D metastatic PDAC (n=60, cutoff 9 Feb 2026): ORR 50% and DCR 97% in second line, median PFS 9.6 months; grade ≥3 treatment-related events 35% (rash, anaemia, stomatitis). First-line combination with gemcitabine/nab-paclitaxel showed high response rates and ctDNA clearance. Phase 3 planning underway.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Cyclophilin-A-mediated tri-complex that covalently engages the G12D mutant aspartate and blocks effector binding in the active state. Connects to KRAS.
1.Zoldonrasib slips into a pocket on KRAS.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Zoldonrasib" OR ABSTRACT:"Zoldonrasib" OR TITLE:"RMC-9805" OR ABSTRACT:"RMC-9805") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Zoldonrasib, not a curated reading list.
Shares Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors, Revolution Medicines, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, KRAS G12C-mutant colorectal cancer.
Shares RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall, KRAS & RAS inhibitors, The undruggable drivers.
Shares Revolution Medicines, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, Daraxonrasib, KRAS & RAS inhibitors.
Shares RAS(ON) inhibitors to convert unresectable pancreatic cancer to resectable, Revolution Medicines, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, Daraxonrasib.
Shares Revolution Medicines, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, Daraxonrasib, Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall.
Shares RAS(ON) inhibitors to convert unresectable pancreatic cancer to resectable, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, Daraxonrasib, KRAS & RAS inhibitors.
Shares Revolution Medicines, Daraxonrasib, KRAS G12C-mutant colorectal cancer, KRAS & RAS inhibitors.
Shares Daraxonrasib, KRAS & RAS inhibitors, The undruggable drivers, RAS / RAF / MEK / ERK (MAPK).